Driving Efficiency & Unlocking Scalability for PRAME Cell Therapy Manufacturing

  • Anzu-cel is TCR T-cell therapy directed against PRAME, a target expressed in more than 50 cancers
  • Scaling out efficiently: horizontal expansion to increase speed and throughput
  • Preparing for commercial manufacturing through operational excellence